Serina Therapeutics Receives FDA IND Clearance for SER-252 Parkinson's Disease Therapy
Key Insights
Serina Therapeutics received FDA clearance for its Investigational New Drug application for SER-252, an investigational therapy targeting advanced Parkinson's disease (search).
The IND clearance enables the company to proceed with regulatory and site-level preparations for a planned Phase 1b registrational clinical trial.
The FDA has aligned on a 505(b)(2) New Drug Application pathway for the program, which allows approval for drugs that partly rely on published literature or FDA findings.
Serina Therapeutics Inc. received FDA clearance for its Investigational New Drug application for SER-252, an investigational therapy for advanced Parkinson's disease (search), marking a significant regulatory milestone for the Alabama-based clinical-stage biotechnology company. The announcement triggered a 34.93% surge in after-hours trading, with shares jumping to $3.67 from a regular trading close of $2.72.
Regulatory Pathway and Clinical Development
The IND clearance allows Serina to move forward with regulatory and site-level preparations for a planned Phase 1b registrational clinical trial of SER-252 in patients with advanced Parkinson's disease (search). The FDA has aligned on a 505(b)(2) New Drug Application pathway for the program, which allows approval for drugs that partly rely on published literature or FDA findings for reference listed drugs.
"FDA clearance of the IND is a major milestone for Serina and underscores the promise of the SER-252 program," said Steve Ledger, Chief Executive Officer of Serina Therapeutics.
POZ Platform Technology
SER-252 is developed using Serina's proprietary POZ Platform (search), a poly(2-oxazoline)-based polymer technology designed to provide controlled drug release through subcutaneous injection. This platform technology represents the company's approach to addressing treatment challenges in advanced Parkinson's disease (search) through innovative drug delivery mechanisms.
Market Performance Context
Despite the positive regulatory news, Serina has faced significant market challenges over the past year. The company's stock has fallen 42.98% over the past 12 months, with a current market capitalization of $29.01 million. The stock trades with a 52-week high of $7.92 and a 52-week low of $1.71, currently positioned at approximately 16.27% of its annual range, placing it closer to its low than its high.
The company's Relative Strength Index (RSI) stands at 48.36, and Benzinga's Edge Stock Rankings indicate that SER has maintained a negative price trend across all time frames, suggesting the stock's decline and weak positioning would require clear confirmation before investors consider significant moves.